Impact Factor
3.47
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.71
410 total citations
h5-index
22
h5 depth signal
Cited share
65.6%
59 of 90
Total citations
410
Citation footprint
Metric signal
3.69
External metric anchor
Self-citation
5.4%
22 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
139
United Kingdom
91
Germany
35
Spain
32
India
29
Citing Fields of Research
Medical Ethics
245
Pharmacology & Toxicology
131
Healthcare Policy
91
Patient Care
86
Oncology
43
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
890
Articles tracked across the journal lifetime
Indexed publication set
90
59 cited publications
Last 12 months
51
4.3 publications/month
Open access share
51.0%
26 OA publications in the last year
Leading citing country
United States
139 citing publications
Leading citing field
Medical Ethics
245 citing publications
Latest tracked publication
26 September 2026
10 recent records available
Coverage & Indexing History
v33n1, Feb. 2019-
v33n1, Feb. 2019- ; Selected citations only before this date
Research Focus & Classification
Indexed Subjects
Medical Ethics
Issuing & Sponsoring Bodies
Contributor
Society of Pharmaceutical Medicine
Contributor
International Federation of Associations of Pharmaceutical Physicians
Broad Categories
Medical Ethics
MeSH Descriptors
Clinical Trials as Topic
Drug Evaluation
Drug Industry
Pharmacology, Clinical
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40290-026-00622-0
Open DOI
Galenic Modification as an Alternative Strategy for Administering Oral Anticancer Drugs: Assessment of Bioequivalence
02
DOI 10.1007/s40290-026-00638-6
Open DOI
Highlights from the 42nd Annual Congress of the German Society of Pharmaceutical Medicine (DGPharMed)
03
DOI 10.1007/s40290-026-00632-y
Open DOI
From Compliance to Strategic Partner: The Transformation of Regulatory Affairs in AstraZeneca Local Affiliates
04
DOI 10.1007/s40290-026-00637-7
Open DOI
When Access is Not Enough: A Timely Book on Pharmacovigilance in Resource-Limited Countries
05
06
07
DOI 10.1007/s40290-026-00635-9
Open DOI
From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment
08
DOI 10.1007/s40290-026-00634-w
Open DOI
New Therapeutic Modalities and Collingridge’s Dilemma
09
10
DOI 10.1007/s40290-026-00625-x
Open DOI
Empowering Medical Affairs Professionals in Their Critical Role in Integrated Evidence Generation Planning
An integrated evidence generation plan (IEGP) can transform the effectiveness of how pharmaceutical companies demonstrate the value of new therapies. Medical Affairs professionals are uniquely positioned to lead and shape an IEGP, levera...
Bibliographical & Catalog Notes
Description based on first issue.
Also issued online.